CN101677983B - 用于预防由于使用PPAR-γ激动剂引起的有害作用的组合物 - Google Patents

用于预防由于使用PPAR-γ激动剂引起的有害作用的组合物 Download PDF

Info

Publication number
CN101677983B
CN101677983B CN2008800173198A CN200880017319A CN101677983B CN 101677983 B CN101677983 B CN 101677983B CN 2008800173198 A CN2008800173198 A CN 2008800173198A CN 200880017319 A CN200880017319 A CN 200880017319A CN 101677983 B CN101677983 B CN 101677983B
Authority
CN
China
Prior art keywords
acid
diabetes
ppar
carnitine
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800173198A
Other languages
English (en)
Chinese (zh)
Other versions
CN101677983A (zh
Inventor
M·卡尔瓦尼
S·迪蒂奥
P·贝纳提
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CN101677983A publication Critical patent/CN101677983A/zh
Application granted granted Critical
Publication of CN101677983B publication Critical patent/CN101677983B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
CN2008800173198A 2007-05-24 2008-04-28 用于预防由于使用PPAR-γ激动剂引起的有害作用的组合物 Expired - Fee Related CN101677983B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07108801.7 2007-05-24
EP07108801 2007-05-24
PCT/EP2008/055171 WO2008141897A1 (en) 2007-05-24 2008-04-28 Composition useful for the prevention of adverse effect due to the use of ppar-gamma agonists

Publications (2)

Publication Number Publication Date
CN101677983A CN101677983A (zh) 2010-03-24
CN101677983B true CN101677983B (zh) 2012-12-26

Family

ID=38668873

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800173198A Expired - Fee Related CN101677983B (zh) 2007-05-24 2008-04-28 用于预防由于使用PPAR-γ激动剂引起的有害作用的组合物

Country Status (10)

Country Link
US (1) US20100305204A1 (enExample)
EP (1) EP2162127A1 (enExample)
JP (1) JP2010527952A (enExample)
KR (1) KR20100017460A (enExample)
CN (1) CN101677983B (enExample)
AU (1) AU2008253134A1 (enExample)
BR (1) BRPI0812306A2 (enExample)
CA (1) CA2687154A1 (enExample)
MX (1) MX2009012429A (enExample)
WO (1) WO2008141897A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102940884B (zh) * 2012-11-19 2013-11-06 上海市肿瘤研究所 一种肝癌细胞的抑制剂及其在抑制肿瘤生长方面的应用
KR102072075B1 (ko) * 2018-06-21 2020-01-31 울산과학기술원 TRIM25을 유효성분으로 함유하는 PPARγ 분해용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1133010B (it) * 1980-05-15 1986-07-09 Sigma Tau Ind Farmaceuti Metodo terapuetico per il trattamento del diabete mellito a insorgenza giovanile e composizione farmaceutica per tale metodo
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
DE69942672D1 (de) * 1998-12-17 2010-09-23 Mindset Biopharmaceuticals Usa Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns
CN1812988A (zh) * 2003-05-13 2006-08-02 斯索恩有限公司 制备噻唑烷二酮衍生物的方法及其化合物
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient

Also Published As

Publication number Publication date
CA2687154A1 (en) 2008-11-27
AU2008253134A1 (en) 2008-11-27
CN101677983A (zh) 2010-03-24
US20100305204A1 (en) 2010-12-02
EP2162127A1 (en) 2010-03-17
JP2010527952A (ja) 2010-08-19
WO2008141897A1 (en) 2008-11-27
BRPI0812306A2 (pt) 2014-11-25
MX2009012429A (es) 2009-12-09
KR20100017460A (ko) 2010-02-16

Similar Documents

Publication Publication Date Title
Goodarzi et al. Metformin revisited: re‐evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents
JP4845740B2 (ja) 糖尿病を治療するための組成物および方法
US20080249168A1 (en) Pharmaceutical composition for gout
US20090054513A1 (en) Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
WO2005027661A1 (en) Compositions for the treatment and prevention of diabetes mellitus
CN103402506A (zh) 用于治疗糖尿病的组合
CN101677983B (zh) 用于预防由于使用PPAR-γ激动剂引起的有害作用的组合物
US20130108673A1 (en) Co-Therapy for Diabetic Conditions
US20120053172A1 (en) Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
CA2448244C (en) Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
HK1139038A (en) Composition useful for the prevention of adverse effect due to the use of ppar-gamma agonists
JPWO2007007757A1 (ja) ＰＰＡＲγアゴニストを含有する医薬組成物
KR102077374B1 (ko) 연하곤란 환자에서 뇌졸중의 치료에서 사용하기 위한 아미노산을 포함하는 조성물
JP5697337B2 (ja) ２型糖尿病の処置に有用な組成物
HUE025394T2 (en) Preparation for use in type 2 diabetes and complications for use in insulin-resistant pre-diabetic patients
Metformin Hydrochloride Tablets et al. Pr METFORMIN TABLETS
Standard et al. PrTEVA-METFORMIN
Agent PrMYLAN-METFORMIN
CN104771403A (zh) 含有齐墩果酸的药物组合物及其在治疗糖尿病中的用途
US20100215635A1 (en) Small molecules to induce weight loss or to reduce weight gain
Tablets et al. Pr AURO-METFORMIN
Met FDA Drug Approvals
Agent BCI METFORMIN
JP2008517872A (ja) 心血管疾患の治療のためのｌ−カルニチンおよびグルコースの使用
HK1135030B (en) Composition useful for the treatment of type 2 diabetes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1139038

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121226

Termination date: 20130428

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1139038

Country of ref document: HK